Mazen,
Even when compared to other biotech companies such as AMGN, MEDI, BGEN, ENMD, IMNR and others, SEPR seems to be faultering behind
This is a very selective list you are looking at. AMGN has buyout rumors, MEDI has a significant new drug approval, BGEN settled a patent dispute and worries about royalty declines have lessened, ENMD is down from 80 <G>, and IMNR had a very significant deal with AGPH. In other words these have all had recent favorable news/rumors of one sort or another. If you look at the broader biotech index, you will see that SEPR has held up very well in comparison.
The fact is there hasn't been any hard news out of SEPR for a while. The last news there was (the Nori trial results) was muted as SEPR was forced by its partnership into big pharma disclosure mode rather than the biotech mode we were used to.
SEPR's price is a struggle between the people who are prepared to look ahead 4 or 5 years and those who want to know what next quarter's loss is going to be. Unless or until I see some reason to change my long-term view of where this company is going to be in 5 years, I am not going to let day-to-day price fluctuations sway my view on the company. I've never sold a share of SEPR yet, and see no reason to do so now.
Peter |
